Targets

GLP-1

23 articles

PharmacologyACS Pharmacology & Translational Science

Review: Adding Exercise to Incretin Drugs Remains Unproven in Obesity

  • A systematic review of 31 studies pooled roughly 10,000 adults with excess weight and compared incretin drugs, exercise, and the two together.
  • Drugs reliably beat placebo or usual care on weight and glycaemia, but few trials tested drug plus exercise head-to-head against drug alone.
  • Exercise regimens varied widely, often amounting to counselling, so any complementary benefit for fitness or weight maintenance is only tentative.
PointsBased on the abstract

Thirty-one studies and almost no head-to-head drug+exercise versus drug-alone arms: the question clinicians actually ask is barely tested. The pharmacologically interesting endpoint is lean-mass preservation during incretin weight loss, which needs DXA or MRI body composition, not scale weight. Until trials use standardized, supervised training with body-composition and fitness readouts, 'add exercise' stays a plausible hypothesis, not evidence.

Industry NewsPfizer / Blackstone Life SciencesBioPharma Dive

Blackstone commits up to $1.5B to fund Pfizer’s monthly obesity shot through Phase 3

  • Blackstone Life Sciences will put up to $1.5B, phased through 2028, into Pfizer’s Phase 3 program for berobenatide, a potentially once-monthly GLP-1 injectable that came with the roughly $10B Metsera acquisition.
  • The money backs as many as 10 pivotal studies; Pfizer owes Blackstone milestones if the drug is approved as a monthly single agent and hits sales goals, paid as multi-year distributions.
  • Pfizer may run head-to-head trials against Zepbound and Wegovy, not just placebo-controlled studies.
PointsBased on public reports

This is Pfizer syndicating the risk of an expensive catch-up bet: it paid up to win Metsera, and now shares the Phase 3 bill so the cash can stay on Eliquis- and Ibrance-patent-cliff priorities. Blackstone’s return rides on approval and sales, so the structure only works if monthly dosing is a real differentiator against Lilly and Novo, who already have oral pills out. The open question is whether head-to-head data arrive early enough to matter commercially.

Industry NewsNovo Nordisk / Eli LillyBioSpace

FDA orders class-wide GLP-1 label update for potential risk of rare eye disease

  • FDA is requiring all approved GLP-1 receptor agonists to add a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to Warnings and Precautions; indications are unchanged.
  • Twelve products are affected, including Wegovy, Ozempic, Zepbound and Mounjaro.
  • A trial meta-analysis found 6.4 NAION events per 100,000 patient-years with GLP-1s versus 3.8 for comparators; FDA found no mechanism in animal data.
PointsBased on public reports

A Warnings-section addition rather than a boxed warning keeps the commercial hit modest, and the absolute difference is small. Still, class-wide wording denies Novo and Lilly any differentiation on eye safety. What's missing is mechanism and per-drug data; watch for ophthalmology-driven prescribing caution in high-risk patients.

Industry NewsBoehringer Ingelheim / Zealand PharmaBioSpace

Boehringer, Zealand's survodutide shows no added heart risk in Phase 3 CV safety trial

  • In the Phase 3 SYNCHRONIZE-CVOT trial (5,530 adults with overweight or obesity and elevated cardiovascular risk), survodutide was non-inferior to placebo on major cardiovascular events.
  • Results were presented at AHA and published in The Lancet; at 72 weeks it also lowered systolic blood pressure and waist circumference versus placebo.
  • GI-related discontinuations ran about 19-21% versus 1.9% on placebo; Zealand attributes this to limited titration flexibility, and analysts flag tolerability as a liability.
  • The data support global regulatory filings for obesity.
PointsBased on public reports

Clearing the CV safety bar de-risks filing, but survodutide arrives behind semaglutide and tirzepatide with GI discontinuations near 20%, which is hard to defend commercially. Its real differentiation is glucagon-driven liver benefit; the MASH data and any gentler titration results will decide whether it is a contender or a follower.

Industry NewsEli LillySTAT News

Lilly's Oral GLP-1 Foundayo Cuts Sleep Apnea Events in a One-Year Study

  • In a one-year trial in patients not using PAP therapy, Foundayo cut the apnea-hypopnea index by 17.8 events per hour versus 4.5 on placebo.
  • About 28% of treated patients reached remission or mild disease, against 13% on placebo.
  • Data were shown at the AHA meeting and published in JAMA; STAT notes the pill does not look as effective as injectable Zepbound.
PointsBased on public reports

Zepbound already holds the sleep apnea label, so the pill's role is breadth: a convenient option for the many apnea patients who also carry obesity, and a way to extend the franchise without needles or cold chain. Expect payers to ask whether a weaker oral effect justifies a new indication, and for Lilly to pitch it as a step-down or maintenance choice.

Industry NewsEli Lilly / Hims & HersBioPharma Dive

Lilly Lets Hims & Hers Prescribe Zepbound and Foundayo at Self-Pay Prices

  • Lilly will offer Zepbound and its oral Foundayo through the Hims & Hers telehealth platform at the same self-pay prices available elsewhere, starting at $299 and $149 a month respectively.
  • Hims previously sold cheaper compounded GLP-1s and changed course in March after a legal challenge from Novo, which struck a similar deal with it.
PointsBased on public reports

Both big GLP-1 makers now use Hims as a cash-pay channel, which turns a former adversary into distribution and removes the compounded-versus-branded argument from the telehealth funnel. For Lilly the signal is price discipline: self-pay tiers are set low enough that volume, not margin per script, is the bet. Watch whether Hims keeps compounded options for 'clinical necessity'.

Industry NewsAmgenBioSpace

Amgen Starts a MariTide Autoinjector Phase 3 as Tolerability Becomes the Test

  • Amgen has begun another Phase 3 trial of home self-administration of subcutaneous MariTide with an autoinjector; ClinicalTrials.gov lists primary completion in June 2027.
  • The MARITIME programme has 10 trials, two more are due to start this year, and the first Phase 3 data are expected in 2027.
  • Analysts are focused on tolerability rather than weight loss; R&D chief Jay Bradner said a conventional single-chamber handheld device is planned.
PointsBased on public reports

Amgen's pitch is dosing as rarely as four times a year, which would separate MariTide from Lilly's and Novo's weekly products, but that only matters if dose escalation is tolerable. The device study is the quiet commercial step: using a conventional autoinjector reduces launch risk if the pivotal data land. Both BMO and Truist describe differentiation as unproven, so the first GI-event data from Phase 3 is the real readout.

PharmacologyBiochemical Pharmacology (Elsevier)

Peptide hitting both GLP-1 and apelin receptors protects neurons in a mouse Parkinson's model

  • A single bifunctional peptide, ELA, fuses an exendin-4 GLP-1 agonist element with apelin to engage both receptor systems.
  • In MPTP-lesioned mice, benchmarked against liraglutide, it improved movement and dampened neuroinflammation.
  • It also preserved striatal synapses and restored mitochondrial fission/fusion balance, beating liraglutide on some readouts but not all.
PointsBased on the abstract

Beating liraglutide only on some readouts in one MPTP model is a thin basis for calling dual agonism better, since acute MPTP recovers spontaneously and barely mimics progressive alpha-synuclein pathology. Without brain exposure, a dose-response, and a mixed GLP-1 plus apelin co-dosing arm, you can't tell synergy from simply higher potency. Next: pharmacokinetics, then a chronic or alpha-syn model.

Computational & AIJournal of Chemical Information and Modeling (ACS)

Consensus ligand- and structure-based virtual screening uncovers chemically diverse GLP-1 receptor agonists, including a small peptide with dual GIPR activity

  • The pipeline combines ligand-based descriptors, multi-fingerprint and electrostatic similarity, pharmacophore models and docking to several receptor conformations, with a consensus rule to pick compounds.
  • It targets the flexible class B1 GLP-1 receptor, where single-method screens tend to be biased and recover few chemotypes.
  • Selected hits were tested in cells, then probed by binding-site mutagenesis and competition binding.
  • Three structurally distinct agonists emerged, one non-peptide and two peptides; a pentapeptide acted as a full agonist, also hit GIPR, but with modest potency.
PointsBased on the abstract

Three hits is a result, but the missing number is hit rate against how many compounds were tested, and against a plain docking-only or similarity-only baseline. Without that, consensus value is unproven. For a team: check whether the pentapeptide's activity is real receptor pharmacology, and whether modest potency leaves room for optimisation.

PharmacologyBritish Journal of Pharmacology (Wiley)

GLP-1 agonists blunt migraine-like pain in mice, in both sexes

  • Repeated nitroglycerin dosing was used to induce a chronic migraine-like state in male and female mice, and three GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) were tested as prophylaxis against the reference drug propranolol.
  • All three reduced mechanical, cold and orofacial pain responses dose-dependently in both sexes, with efficacy similar to propranolol and no change in the metabolic readouts, whereas propranolol caused a male-specific metabolic effect.
  • For semaglutide, pharmacological blockade and brainstem/trigeminal ganglion mRNA analysis pointed to sex-dependent involvement of opioid and endocannabinoid pathways.
PointsBased on the abstract

Three drugs of one class working equally well is a nicer signal than any single compound, and including females is the right call for a pain model. But the nitroglycerin paradigm is a hypersensitivity readout, not a migraine attack, and the mouse doses aren't mapped to human exposure. Before I'd believe it, I'd want to know how much is central GLP-1R action and how much is just weight or glycaemic change in a model this noisy.

Industry NewsEli Lilly / Novo NordiskBioPharma Dive

Lilly's Retatrutide Tops Ozempic Head-to-Head in Type 2 Diabetes

  • Lilly's Phase 3 TRANSCEND-T2D-2 pitted triple-agonist retatrutide against Ozempic 2 mg in roughly 1,300 adults with type 2 diabetes over 80 weeks, and hit its primary and key secondary endpoints.
  • Both retatrutide doses cut A1C more than Ozempic and produced about twice the weight loss; the top dose carried more side effects and discontinuations.
  • The trial was open-label and the data are company topline; Lilly plans regulatory filings in early 2027.
PointsBased on public reports

A head-to-head win over the diabetes market's reference product is the evidence payers and prescribers have been waiting for, and it lands on Novo's home turf rather than in obesity. The tolerability gap at the top dose is the caveat to watch: if dropouts hold up in full data, the 9 mg dose may be the commercial workhorse.

Industry NewsNovo Nordisk / Eli LillyBioPharma Dive

Judge Won't Pull Lilly's Obesity Ads as Novo Fails to Show Harm

  • A federal judge refused Novo Nordisk's request for a preliminary injunction against Lilly's comparative Zepbound advertising.
  • Novo failed to show harm: Wegovy prescriptions held steady during the April-July campaign, and the ads acknowledged a higher-dose Wegovy exists.
  • Novo says the order does not decide whether the ads are false; its July false-advertising suit continues.
PointsBased on public reports

Flat Wegovy prescriptions through a months-long Lilly campaign is the quiet finding: it undercuts the idea that comparative messaging is moving share in obesity, and shows how hard injunctions are to win without measurable harm. The July suit still runs, but in a two-player GLP-1 market, expect the real contest to stay on data and access, not in court.

Industry NewsCorxel Pharmaceuticals / Amanat Acquisition Corp. / Vincentage PharmaBioPharma Dive

Corxel Heads to Nasdaq via SPAC With Oral GLP-1 and $300M Backing

  • Corxel will list in the US by merging with SPAC Amanat Acquisition Corp., alongside a $300 million private investment.
  • The listed company will carry two obesity assets: CX11, an oral GLP-1 in-licensed from China's Vincentage, and a preclinical amylin candidate.
  • A global Phase 3 for CX11 could begin as early as Q1 2027; its non-obesity assets stay in a private parent.
PointsBased on public reports

Two listed assets, but only CX11 is heading toward Phase 3; the amylin candidate is still preclinical, so this is essentially a single-molecule story. Ring-fencing non-obesity assets in a private parent signals a deliberate pivot to a pure obesity identity, and it shows China-sourced in-licensing is now a route to a US listing, not just to pharma partnerships.

PharmacologyChemical Research in Toxicology (ACS)

PFOS found in human pancreas, disrupts insulin secretion

  • In organ donors, PFOS was found in nearly all pancreas samples, far more often than PFHxS or PFOA; mouse data also showed PFOS accumulating in pancreas.
  • In cell lines and islets, prolonged high-dose PFOS suppressed insulin secretion, while acute exposure boosted it in mouse and some human islets.
  • A GLP-1 receptor antagonist partly blunted the acute surge, and in mice PFOS raised insulin only alongside glucose, so the model chosen shapes the result.
PointsBased on the abstract

Biphasic data are hard to build on: acute PFOS raised insulin, prolonged high doses suppressed it, and the mouse response needed glucose present. Pancreatic concentrations measured alongside these doses are missing, so the human relevance of the in vitro exposures stays open. The partial GLP-1R antagonist block is a lead worth following, though likely one arm of the mechanism.

Industry NewsBoehringer Ingelheim / Zealand PharmaFierce Biotech

Survodutide's second underwhelming phase 3 read-out knocks Zealand's shares

  • Boehringer Ingelheim and Zealand's survodutide produced weight loss of up to roughly 13% in people with diabetes in phase 3.
  • Zealand's shares fell sharply after the data, which landed a day after Lilly's eloralintide–tirzepatide combination read-out.
  • Gastrointestinal side effects drove about 18% of treated patients to stop, keeping tolerability in question.
  • It is the second recent disappointment for the compound after earlier SYNCHRONIZE-1 data.
PointsBased on public reports

The efficacy sits between semaglutide 2.4 mg and top-dose tirzepatide, but timing is brutal: Lilly's amylin combination landed 24 hours earlier at a far higher weight-loss level. With roughly one in five patients dropping out on GI effects, survodutide's remaining angle is MASH, where glucagon activity is the differentiator, not raw weight loss. Expect investors to price Zealand on that liver story and on how Boehringer positions dosing and titration.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

What first-generation oral GLP-1 drugs teach about designing the next ones

  • Reviews nonpeptidic GLP-1 receptor agonists that reached the clinic, including danuglipron, lotiglipron, DA-302168S and orforglipron, as case studies of how each solved the oral-delivery problem.
  • Notes the design challenges these first-generation molecules still leave open.
  • Proposes next-generation approaches: peptidomimetic design, multi-target agonists, and exploiting orthosteric-allosteric cooperativity.
  • Covers practical aspects such as screening cascades, preclinical species choice, formulation and early safety assessment, with relevance to other difficult GPCRs.
PointsBased on the abstract

Four clinical chemotypes, four different answers to the same problem: a class B GPCR built to bind a large peptide. What I want from a review like this is the SAR logic behind each survivor. Orthosteric-allosteric cooperativity is the idea I'd chase, since it could loosen the potency-versus-permeability tradeoff. Whether it holds up depends on the screening cascade and species choice, which is where programs usually stumble.

Industry NewsNovo Nordisk / Jiangsu Hengrui PharmaceuticalsEndpoints News

Novo Pays $300M Upfront for Hengrui's Weekly Oral GLP-1/GIP Agonist

  • Novo gets exclusive rights outside mainland China, Hong Kong, Macau and Taiwan to HRS-1596, a once-weekly oral GLP-1/GIP dual agonist, for $300M upfront and up to $2.3B in milestones plus royalties.
  • The asset is Phase 1-ready, with Chinese clearance to start trials in weight management and type 2 diabetes; closing is expected in Q4 2026.
PointsBased on public reports

Paying $300M upfront for a molecule that hasn't dosed a human outside China shows how badly Novo wants an oral follow-on while Lilly presses its lead. It also fits a pattern of buying de-risked-enough optionality from outside rather than building it, after smaller deals like Nanexa. Weekly oral bioavailability is the real technical risk, and the milestone-heavy structure shields Novo if it fails.

Industry NewsRocheFierce Biotech

Roche's Enicepatide Hits Phase II Goals in Diabetes and Obesity Trial

  • Enicepatide (CT-388), Roche's dual GLP-1/GIP receptor agonist, met both primary endpoints in a Phase II trial in type 2 diabetes with overweight or obesity.
  • At 48 weeks, the top 24 mg dose drove dose-dependent weight loss near 15% with no plateau, plus strong glycemic improvement.
  • Most high-dose patients reached near-normal HbA1c, and Roche is now advancing Phase III programs (ENITH-1, ENITH-2) plus a glycemic-control study.
PointsBased on public reports

Roche just cashed in its $2.7B Carmot acquisition: a 15% weight-loss curve still climbing at 48 weeks puts enicepatide in contention with Lilly's retatrutide and Novo's CagriSema, not just chasing tirzepatide. More importantly, it hands Roche a credible re-entry into metabolic disease after sitting out the incretin boom — Phase III now becomes the real test of manufacturing and commercial scale-up against entrenched leaders.

Industry NewsNovo NordiskSTAT News

Novo Nordisk May Have Landed a Sweeter Deal in Medicare's GLP-1 Bridge Pilot

  • Medicare's GLP-1 Bridge pilot, launched under the Trump administration, sets a flat $50 monthly co-pay for obesity drugs — including Novo Nordisk's Wegovy and Eli Lilly's Zepbound and orforglipron — for Part D beneficiaries from July 2026 to December 2027.
  • STAT reporting suggests Novo Nordisk's negotiated terms under the pilot may be more advantageous than initially disclosed, potentially outperforming Lilly's arrangement.
PointsBased on public reports

A pricing edge over Lilly in this two-horse race is worth more than the headline $50 co-pay — share captured under a fixed-price pilot compounds fast, and better fine print (rebates, volume triggers) beats a flashier price point. Read this as both companies treating government-negotiated terms as a template to refine, not a one-off concession, ahead of oral GLP-1 competition.

Industry NewsNovo NordiskSTAT News

Novo Nordisk Unveils 2030 Growth Strategy at Capital Markets Day; Shares Slide on Thin Details

  • At its Sept. 21, 2026 Capital Markets Day in London, new CEO Mike Doustdar unveiled a strategy to scale Novo Nordisk's obesity franchise and diversify the pipeline beyond diabetes/obesity.
  • Targets include 10x capacity for oral GLP-1 obesity therapy, serving more than 60 million patients globally by 2030, and launching 5+ "multi-blockbuster" products by 2030.
  • Novo also set a goal of more than DKK150 billion (about $23 billion) in risk-adjusted pipeline sales by 2035, and pledged to be "more active" in business development (licensing/M&A) and direct-to-consumer sales models.
  • The moves are aimed at addressing investor concern that Novo is too reliant on its GLP-1 franchise.
  • Market reaction was negative: shares fell sharply intraday (reports of roughly 5-9%), as analysts said the plan was strong on ambition but thin on new specifics, amid rising competition from Eli Lilly's tirzepatide/Zepbound.
PointsBased on public reports

This is the payoff to last week's "Novo" rebrand, and the market just delivered its verdict: a 2030/2035 target set with no concrete near-term catalyst is guidance, not proof, so shares got sold rather than bought. The real signal isn't the capacity or blockbuster math — it's the pledge to get "more active" in business development. That's Doustdar admitting the internal pipeline can't diversify fast enough on its own, especially with Lilly's tirzepatide/Zepbound machine still taking share while Novo's oral GLP-1 scale-up remains years out. Ambition claims parity; execution proves it. The next real test isn't another investor-day slide — it's whether Doustdar actually closes a deal or lands an R&D readout in the coming quarters, or whether this was sentiment management dressed up as strategy.

Industry NewsNovo NordiskFiercePharma

Novo Nordisk Rebrands as 'Novo' in Public-Facing Identity Shift

  • Novo Nordisk announced on September 14, 2026 that it will use "Novo" as its public-facing brand name, dropping "Nordisk" from consumer-facing communications; the legal corporate name, Novo Nordisk A/S, is unchanged.
  • The rebrand includes a new tagline, "Lasting Health Starts Now," a refreshed internal culture framework called "The Novo Way," and an updated version of the company's Apis bull logo, now facing forward.
  • CEO Mike Doustdar, roughly a year into his tenure, is leading the rebrand as part of a broader corporate turnaround and simplification strategy.
  • The move comes amid intensifying competition in the GLP-1/obesity drug market and recent stock pressure.
  • The announcement was timed ahead of the company's capital markets day, scheduled for September 21, 2026.
PointsBased on public reports

Timing is the tell: a name change lands seven days before capital markets day, and rebrands are the cheapest lever a new CEO can pull — no pipeline risk, no payer negotiation, no manufacturing capex. Doustdar needs the CMD to convert cosmetics into substance: a credible answer to Lilly's tirzepatide share gains and Zepbound pricing pressure, a pipeline update beyond semaglutide (oral GLP-1, amycretin, next-gen combos), and cost detail that shows "simplification" is more than messaging. Watch three things at CMD: guidance revisions, R&D readouts with real differentiation, and whether "The Novo Way" comes with organizational or capital-allocation changes, not just culture-deck language. If the identity refresh isn't paired with share-defending data, it's a signal management is managing sentiment, not fundamentals.

Industry NewsNovo Nordisk / Ascendis PharmaFierce Biotech

Novo Nordisk Exits $285M Obesity Drug Deal with Ascendis Pharma

  • Novo Nordisk has terminated its partnership with Ascendis Pharma to co-develop a once-monthly GLP-1 receptor agonist for obesity and diabetes.
  • The collaboration was signed in November 2024 and licensed Ascendis's TransCon sustained-release drug delivery platform to Novo for its lead once-monthly program.
  • Under the original agreement, Ascendis was eligible for up to $285 million in combined upfront, development, and regulatory milestone payments, plus potential tiered royalties.
  • The goal was a monthly-dosed treatment intended to compete with existing daily and weekly GLP-1 drugs on the market.
  • Novo ended the collaboration less than two years after it began, with no monthly GLP-1 product having resulted from the partnership.
PointsBased on public reports

A sub-$300M deal dying in under two years, with no candidate ever reaching the clinic, is a cheap off-ramp — Novo exits with minimal sunk cost, unlike a late-stage termination. That's the tell: this reads less as a verdict on Ascendis's TransCon chemistry and more as Novo reprioritizing internally under intense competitive pressure from Lilly's tirzepatide franchise and oral orforglipron. Killing a monthly-dosing bet also raises a sharper question: is weekly GLP-1 dosing already "good enough," with the real prize shifting to oral convenience instead? For Ascendis, the financial hit is small but the strategic one isn't — losing a big-pharma validation partner for TransCon undermines the platform story just as investors want proof the delivery tech, not just the molecule, is what pharma will pay up for.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

From Injections to Pills: A Blueprint for Oral GLP-1 Drugs

  • This J. Med. Chem. perspective synthesizes lessons from four clinical-stage oral, nonpeptidic GLP-1 receptor agonists—danuglipron, lotiglipron, DA-302168S, and orforglipron—to outline a design blueprint for next-generation candidates.
  • It frames a broader modality shift in metabolic disease therapeutics: from injectable peptide GLP-1RAs toward oral small molecules that could improve dosing convenience and patient acceptance.
  • Orforglipron is highlighted as the first oral small-molecule GLP-1RA to reach approval, marking a proof-of-concept milestone for the class.
  • The authors distill recurring structure-activity relationship tradeoffs among these first-generation candidates—balancing receptor potency, tolerability, and oral bioavailability—that shaped each program's clinical trajectory.
  • Based on these comparisons, the review proposes design principles intended to guide future medicinal chemistry efforts toward improved oral GLP-1RAs.
PointsBased on the abstract

GLP-1R's orthosteric pocket is deep and peptide-shaped — basically undruggable at drug-like MW/logP, so all four of these (danuglipron, lotiglipron, DA-302168S, orforglipron) work through allosteric or biased engagement rather than mimicking the peptide directly. That's the clever workaround, but it means potency, selectivity, and clean signaling bias have to be re-optimized empirically each time instead of inherited from orthosteric geometry. GI tolerability tracking with off-target signaling bias is still the recurring failure mode — lotiglipron's discontinuation is the cautionary tale here. No convergent scaffold yet: four programs, four distinct chemotypes, still bespoke SAR rather than a template anyone can reuse. Orforglipron's approval is proof-of-concept, not a formula. Expect the same peptide-to-oral-small-molecule chase to hit GIP and glucagon receptor programs next.